Ipamorelin is a synthetic peptide developed to stimulate the body's natural release of growth hormone, a hormone involved in growth, metabolism, and tissue maintenance. It belongs to a group of compounds known as growth hormone secretagogues, meaning substances that encourage the body to release growth hormone rather than supplying the hormone directly. Ipamorelin has attracted scientific interest in growth hormone regulation, metabolic signalling, and the body's natural growth-related processes.

Research has examined how ipamorelin interacts with the ghrelin receptor, a receptor involved in controlling growth hormone release and other metabolic signals. Ghrelin is a naturally occurring hormone often associated with hunger, but its signalling system also helps regulate growth hormone. Early experiments suggested that ipamorelin could stimulate growth hormone release with less activity involving certain other pituitary hormones than some older experimental compounds.

Ipamorelin has been investigated through laboratory studies, animal research, and limited human clinical investigations. Early studies examined its ability to influence growth hormone levels, while later clinical research explored its effects on recovery of bowel function following abdominal surgery. These investigations provided information about its biological activity, although they did not establish broad benefits for body composition, muscle growth, or physical recovery.

Although ipamorelin has demonstrated activity in growth hormone research, its clinical evidence remains limited and it is not an approved treatment for general growth hormone enhancement or anti-aging. Changes in hormone measurements do not necessarily translate into meaningful improvements in health or physical performance. Further controlled research is needed to clarify its long-term safety, effectiveness, and potential medical applications.